Israeli Drug Development Companies Are Poised for 505(b)(2) Development Process, Camargo Expert Says
Many Israeli pharmaceutical executives recently learned that the 505(b)(2) development process is an important tool that can significantly reduce costs and shorten the timeline for approval of new drugs, adding substantially to ROI.
Many Israeli pharmaceutical executives recently learned that the 505(b)(2) development process is an important tool that can significantly reduce costs and shorten the timeline for approval of new drugs, adding substantially to ROI.
“Israel is known for innovation, and Israeli developers offer a wide range of drug candidates with good market potential and an opportunity to gain U.S. FDA approval through 505(b)(2),” said Ken Phelps, president and CEO of Camargo Pharmaceutical Services and a leading international authority on the development process.
Speaking before an enthusiastic group of more than 40 C-level executives at an invitation-only drug development seminar in Tel Aviv Dec. 9, Phelps said development under 505(b)(2) is ideal for drugs making a change from a previously approved drug because it allows utilizing selected data from studies in the public domain.
“For new indications, drugs that enhance some aspect of an existing drug, drugs with dosage changes or new active ingredients, prodrugs, combination drugs or drug-device combinations, 505(b)(2) can be an attractive alternative,” Phelps said.
As head of a full-service organization specializing in 505(b)(2) development, Phelps stressed the importance of careful planning to evaluate both the scientific and commercial feasibility of proposed drug products.
“A step-by-step plan is essential to success,” Phelps said, “but success can mean a differentiated product with three, five or even seven years of market exclusivity and great potential for ROI.”
Phelps’ remarks provoked an enthusiastic response from the audience. “In two hours [our] team got answers to issues they were debating for months,” said Dr. Sharon Cohen-Vered, head of CMC at NeuroDerm.
Dr. Roni Mamluk, CEO at Chiasma added, "Even for a very experienced professional in the field, the event was an eye-opener."
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials
September 10th 2024The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.
